AddedRisk Factors
•Some of our products are sold to clinical call points outside our core vascular surgeon customer base, and our sales representatives may not be successful in expanding adoption in those markets.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
•Cybersecurity incidents, data breaches, failures of information technology systems, and reliance on third-party service providers could disrupt operations, compromise sensitive information, expose us to regulatory actions or litigation, and harm our reputation.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
•The ongoing implementation and expansion of our enterprise resource planning system presents operational and internal control risks that could disrupt business processes and financial reporting.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
•Our tissue processing, preservation and cryopreservation services are subject to unique operational, sourcing and regulatory risks, including donor tissue availability, accreditation requirements and compliance with complex human tissue laws.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedRisk Factors
Significant disruptions of information technology systems or breaches of information security systems could adversely affect our business.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
While we have invested, and continue to invest, in our information technology and information security systems and employee information security training, there can be no assurance that our efforts will prevent all security breaches, phishing/fraud attempts, service interruptions, or data losses. Although we are not aware of having experienced any prior material data breaches, regulatory non-compliance incidents, or cyber security incidents, we may in the future be impacted by such an event, exposing our clients and us to a risk of someone obtaining access to our information, to information of our clients or their customers, or to our intellectual property; disabling or degrading service; or sabotaging systems or information. Any such security breach could result in a loss of confidence in the security of our services; damage our reputation; disrupt our business; require us to incur significant costs of investigation, remediation and/or payment of a ransom; lead to legal liability; negatively impact our future sales; and result in a substantial financial loss.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Joseph P. Pellegrino, Jr. has served as our Chief Financial Officer since 2007 and a member of our Board of Directors since 2016. In August 2024, Mr. Pellegrino announced that he will retire as Chief Financial Officer as of March 7, 2025. He will remain a member of the Board of Directors. Mr. Pellegrino will be replaced by Dorian LeBlanc.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Employee equity awards may provide less of an employee retention benefit if the price of our common stock is unable to grow beyond the record highs it has recently achieved.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
The price of our common stock experienced significant gains in 2024, reaching an all-time high in November 2024 of $108.09, nearly double where the stock began at the beginning of the year. Our market capitalization currently exceeds $2 billion. A meaningful portion of compensation provided to our more senior employees is provided in the form of equity awards that consist of restricted stock units, or RSUs, performance-based restricted stock units, or PSUs, and stock options. These rewards are partially intended to encourage retention. Historically we have enjoyed high levels of employee retention, particularly at senior levels. If we are unable to grow the price of our common stock, the retention value of employee equity awards could be diminished and our employee retention could suffer.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedRisk Factors
Each The majority of our executive team, including our Chief Executive Officer, Chief Financial Officer, our President, and our Senior Vice President, Operations have President of Operations, has significant tenure with the company; are is highly knowledgeable of the Company’s business, operations, budgeting, strategy, product offerings, resources, and personnel; maintain and maintains key external relationships on behalf of the Company; and have been integral to the success of the Company.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
The As of December 31, 2025, the conversion rate is 8.3521 8.3676 shares of common stock per each $1,000 principal amount of Notes, or approximately $119.73 $119.51 per share, a 30% premium over the closing price on the date of pricing of the Convertible Notes. share.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although 510(k) clearances have been obtained for nearly all of our current products that require such clearances, the FDA may condition, limit or prohibit our sales of these products if safety or effectiveness problems develop with the devices.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We have such licenses or registrations, and we believe we are in compliance with applicable state laws and regulations relating to clinical laboratories and tissue banks that store, preserve, and distribute donated human tissue designed to be used for medical purposes in human beings.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although we offer training for physicians, physicians in accordance with our products' instructions for use, we do not require that physicians be trained in the use of our products, and physicians may use our products incorrectly or in procedures not contemplated by us. us or our products' instructions for use.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We However, we have not established a minimum dividend payment level for our common stockholders and there are no assurances of our ability to pay dividends to common stockholders in the future.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We rely on sole- and limited-source suppliers for many of our important components and certain products, including our XenoSure biologic patch, VascuCel and CardioCel biologic patch, Artegraft biologic graft, vascular graft and Omniflow biosynthetic vascular graft, and RestoreFlow allografts. graft.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our Fox River Grove, Illinois Grove operations, as well as certain operations in our Burlington facility, must comply with the FDA’s current Good Tissue Practices.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our Chief Executive Officer and Chairman of the Board controls approximately 8.5% 7.3% of our outstanding common stock as of December 31, 2024. 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
While we have largely completed the implementation of a new enterprise resource planning, or ERP, system in the United States, States and United Kingdom, we are continuing to work on expand its adoption internationally.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We have received UKCA marks for 16 18 of our 23 22 product lines. lines so far.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
The segments in which we primarily operate are competitive, subject to change, and affected by new product product, and in some cases, procedure, introductions.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If those regulatory bodies feel believe that we have failed to comply with regulatory standards, there can be no assurance that any approval, licensure, or registration will not be subsequently withdrawn, suspended or conditioned upon extensive post-market study requirements, even after having received marketing approval or clearance or licenses and registrations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Our discussion and analysis of our financial condition and results of operations for 2025 as compared to 2024 are discussed below. For a discussion of our financial condition and results of operations for 2024 as compared to 2023, please refer to Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our 2024 Annual Report on Form 10-K, except as set forth below.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Separately, our regulatory efforts to maintain approvals in the EU and the United Kingdom (UK) have succeeded ahead of the full EU transition from the Medical Device Directive (MDD) to the Medical Device Regulation (MDR) and the UK transition to the United Kingdom Conformity Assessed (UKCA) mark. As of January 2026, we have 22 MDR CE marks and 18 UKCA approvals. Those 22 CE and 18 UKCA marks represent substantially all of our product approvals in the EU and UK. The European Commission has designated the end of 2028 as the final MDR CE mark transition deadline.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Additionally, we provide cryopreservation services for our RestoreFlow allografts primarily in the US, the UK, and Canada. In October 2025, we received approval from the German authority on tissue banking to allow sale of these services in the German market.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
advertising and product promotions, direct mail, and other marketing costs. Additionally, sales and marketing expense includes customer service department personnel charges.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
On July 4, 2025, President Donald Trump signed the One Big Beautiful Bill Act ("OBBA") into law, which is considered the enactment date under US GAAP. Key corporate tax provisions include the restoration of 100% bonus depreciation for qualifying assets, immediate expensing for domestic research and experimental expenditures, changes to Section 163(j) interest limitations, updates to U.S. tax rules on international sales and operations, amendments to energy credits, and expanded Section 162(m) aggregation requirements.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In 2025, we implemented provisions of the OBBA, fully recognizing the deduction of domestic research and experimental expenditures previously capitalized under Section 174 of the Internal Revenue Code. As a result of this
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
implementation, we adjusted our deferred tax assets and deferred tax liabilities to reflect the change in tax treatment for these expenditures. The impact of these adjustments is reflected in our 2025 tax provision and financial statements. We will continue to monitor future legislative developments and assess their impact on our tax position and financial reporting.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
date. We have the right to elect to settle conversions either in cash, shares of common stock, or in a combination of cash and shares of its common stock.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
As part of the Company’s normal course of business, the Company has commitments to purchase approximately $9.1 million of inventory through 2026. These purchases are to be used in the normal course of business and do not represent excess commitments or loss contracts.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of consolidated financial statements requires management to make estimates and judgments that affect
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
the reported amounts of assets and liabilities, net sales, costs and expenses, and related disclosures. On a periodic basis, we evaluate our estimates, using authoritative pronouncements, historical experience and other assumptions as the basis for making estimates. We have described our significant accounting policies in Note 1 to our consolidated financial statements included in this Form 10-K.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
We believe the following critical accounting policies involve a significant level of estimation uncertainty and judgments that are reasonably likely to have a material impact on our consolidated financial statements. We base our judgments and estimates on historical experience, current conditions and other reasonable factors. Actual results could differ from those estimates under different assumptions or conditions.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedMD&A
To assist us in evaluating our business strategies, we monitor long-term technology trends in the peripheral vascular device market. Additionally, we consider the information obtained from discussions with the medical community in connection with the demand for our products, including potential new product launches. We also use this information to help determine our competitive position in the peripheral vascular device market and our manufacturing capacity requirements.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Separately, in July 2024, we received MDR CE marks allowing for the continued sale of ten devices into the EU. Previously we had obtained four MDR CE marks. In January 2025, we received MDR CE marks to market Burlington-manufactured CardioCel and VascuCel devices in the EU. In total, we expect to receive 23 MDR CE marks by the end of 2025. The European Commission has designated the end of 2028 as the final MDR CE mark deadline.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
In October 2018, we acquired the Cardial business from Becton Dickinson. Cardial manufactured polyester vascular grafts, valve cutters and surgical glue at its St. Etienne, France facility. In June 2022, we closed the St. Etienne factory to streamline manufacturing operations and to reduce expenses. We are transitioning Cardial graft sales to our Burlington-manufactured AlboGraft product for additional cost savings and improved margins.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Finally, from time to time we enter into distribution agreements of complementary product lines with the option to acquire the product line in the future:
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Restructuring. For the year ended December 31, 2024, there were no restructuring expenses. On June 30, 2022, we ceased operations at our St. Etienne, France factory. The closure resulted in a restructuring charge of $3.1 million for the year ended December 31, 2022. These charges consisted primarily of employment termination costs, impairment of fixed assets and inventory, and third-party costs. For the year ended December 31, 2023, we recorded additional restructuring expenses related to this closure of $0.5 million. The additional expenses consisted primarily of employment termination, settlement, legal, and other third-party costs. As a percentage of sales, restructuring expenses was less than 1% for the year ended December 31, 2023.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
We monitor the mix of profitability by tax jurisdiction and adjust our annual expected rate on a quarterly basis as needed. While it is often difficult to predict the final outcome or timing of the resolution for any particular tax matter, we believe our tax reserves reflect the probable outcome of known contingencies.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminated the option to deduct research and development expenditures immediately in the year incurred and requires taxpayers to amortize such expenditures over five years for tax purposes. This provision resulted in a cash tax liability for the 2024 tax year of approximately $0.8 million. Our net deferred tax assets increased in 2024 by approximately $0.9 million as a result as well. This provision is also expected to increase our 2025 cash tax liability. The actual impact on 2025 cash tax liability will depend on the amount of research and development expenses paid or incurred in 2025 among other factors. The impact will continue over the five-year amortization period, but will decrease ratably over the period.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Restructuring. For the year ended December 31, 2023, restructuring expenses were $0.5 million. On June 30, 2022, we ceased operations at our St. Etienne, France factory. The closure resulted in a restructuring charge of $3.1 million for the year ended December 31, 2022. These charges consisted primarily of employment termination costs, impairment of fixed assets and inventory, and third-party costs. For the year ended December 31, 2023, we recorded additional restructuring expenses related to this closure of $0.5 million. The additional expenses consisted primarily of employment termination, settlement, legal, and other third-party costs. As a percentage of sales, restructuring expenses was less than 1% for the year ended December 31, 2023, down from 2% in the prior period.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
The Company incurred a cash tax liability for the 2023 tax year of approximately $0.7 million and an increase in our net deferred tax assets for the 2023 tax year by approximately $0.8 million as a result of the Tax Cuts and Jobs Act of 2017.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of our consolidated financial statements and related disclosures require us to make estimates, assumptions and judgements that affect the reported amounts of assets, liabilities, sales, costs and expenses, and related disclosures. We evaluate our estimates on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
While our significant accounting policies are described in more detail in Note 1 to our consolidated financial statements included in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgements and estimates used in the preparation of our consolidated financial statements.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
We account for income taxes under the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred taxes are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The provision for income taxes includes taxes currently payable and deferred taxes resulting from the tax effects of temporary differences between the financial statement and tax bases of assets and liabilities. We maintain valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in the valuation allowances are included in our tax provision in the period of change. In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings, carry-back and carry-forward periods, and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedMD&A
Recent approvals include the approval approvals to sell the XenoSure patch for carotid indication in Japan in May 2023, and the Pruitt Irrigation Occlusion Catheter in China in October 2023, the XenoSure patch for cardiac indication in China in December 2024, and 2023; approvals to sell the Artegraft bovine graft in Thailand and Malaysia in August 2024 and in South Africa in October 2024. 2024, and the XenoSure patch for cardiac indications in China in December 2024; and approvals to sell the Artegraft bovine graft in the European Union (EU) in April 2025, Australia in June 2025, and Canada in December 2025, the Pruitt Aortic Occlusion Catheter in the EU in May 2025, and the Pruitt Occlusion Catheter in China in June 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash provided by operating activities was $44.1 $81.3 million for the year ended December 31, 2024, 2025, consisting of $44.0 $57.7 million net income, adjusted for non-cash items of $20.2 $25.3 million (including primarily depreciation and amortization of $9.7 $10.4 million, stock-based compensation of $6.6 $7.8 million, provisions for inventory write-offs and credit losses of $3.9 $3.5 million, provision for deferred income taxes of $2.3 million, amortization of issuance costs on convertible senior notes of $0.9 million, and unrealized mark-to-market loss on equity investments of $0.5 million, offset by foreign currency transaction effect on income of $0.4 million, and fair value adjustments to contingent consideration obligations of $0.1 million, offset by a provision for deferred income taxes of $0.5 $0.2 million), as well as cash used for working capital of $20.1 $1.7 million.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We recorded a tax provision of $17.5 million on pre-tax income of $75.2 million for the year ended December 31, 2025, compared to $12.8 million on pre-tax income of $56.9 million for the twelve months year ended December 31, 2024, compared to $9.4 million on pre-tax income of $39.5 million for the twelve months ended December 31, 2023. 2024.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Our cash and cash equivalents are liquid short-term marketable securities primarily include corporate debt securities, U.S. government agency securities, money market investments with maturities of 90 days or less at the date of purchase and consist primarily held outside of our operating bank accounts. accounts, and a short-duration bond equity fund.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The net cash used for working capital was driven by increases in inventory and other deferred costs of $10.6 million, $7.2 million and increases in accounts receivable of $6.4 $2.9 million, offset by increases in accounts payable and other liabilities of $4.2 million, decreases in prepaid expenses and other assets of $2.3 $2.4 million, and decreases increases in accounts payable and other liabilities accrued interest of $0.8 $1.8 million.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Gross profit increased $23.9 $27.6 million, or 19%, 18%, to $178.5 million for the year ended December 31, 2025, as compared to $150.9 million for the year ended December 31, 2024, and gross margin increased by 290 basis points to 68.6% 71.5% in the period. period, as compared to 68.6% for the year ended December 31, 2024.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The increase was driven primarily by increased sales of grafts of $5.1 million, which includes the launch of Artegraft, shunts of $2.8 million, catheters of $2.1 million, patches of $3.3 million, grafts of $3.0 million, shunts of $1.9 $1.8 million, and valvulotomes of $1.1 $1.3 million.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Other income (expense) primarily includes interest income and expense, dividend income, realized gains (losses) from the sale of debt and equity investments, unrealized gains (losses) from equity investments, interest expense for the convertible senior notes, foreign currency gains (losses), and other miscellaneous gains (losses).
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We have been preparing for this transition since 2022 and have hired an experienced consulting team to assist in this transition, and, in In the U.S., United States, we transitioned from our legacy ERP system to our newly implemented Microsoft Dynamics D365 system in February 2024.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Our cost Cost of sales consists primarily of manufacturing personnel, personnel wages, raw materials and components, depreciation of property and equipment, and other allocated manufacturing overhead, as well as the freight expense we pay to ship products to customers. including an allocation of our quality department expenses.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Net sales increased by $26.4 $29.7 million, or 14%, to $249.6 million for the year ended December 31, 2025, compared to $219.9 million for the year ended December 31, 2024, compared to $193.5 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We believe that our cash, cash and cash equivalents, investments, short-term marketable securities, and the interest we earn on these balances will enable us to fund our operating expenses, capital expenditures requirements, and Convertible Note interest payments for at least twelve months following the filing of our annual report on this Form 10-K and, together with our anticipated future cash, cash equivalents, and short-term marketable securities, to meet our known long-term cash requirements.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesMD&A
Under the agreement, we can could distribute the products for three years with an option to acquire Elutia’s worldwide cardiovascular porcine patch business during the second and third year years of the agreement.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesMD&A
In certain limited cases our products are held on consignment at a hospital or clinic prior to purchase; in those instances we recognize revenue at the time the product is used in surgery rather than at shipment.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new